- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00307827
Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)
April 26, 2012 updated by: Abbott
A Phase 2, Randomized, Double-blind, Multicenter, Dose-exploration Study of Visilizumab in Subjects With Intravenous Steroid-refractory Ulcerative Colitis
The purpose of this study is to assess the efficacy, immunogenicity, and safety of various doses of visilizumab in subjects with intravenous steroid-refractory ulcerative colitis (IVSR-UC) and to evaluate optimal dosing.
Study Overview
Detailed Description
PDL BioPharma, Inc. was formerly known as Protein Design Labs, Inc.
Study Type
Interventional
Enrollment (Actual)
38
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Hamilton, Canada, L8N 3Z5
- Site Reference ID/Investigator# 71875
-
Winnipeg, Canada, R3A 1R9
- Site Reference ID/Investigator# 71873
-
-
-
-
-
Osijek, Croatia, 31 000
- Site Reference ID/Investigator# 72338
-
Zagreb, Croatia, 10000
- Site Reference ID/Investigator# 72334
-
-
-
-
-
Bologna, Italy, 40138
- Site Reference ID/Investigator# 72345
-
-
-
-
-
Moscow, Russian Federation, 111123
- Site Reference ID/Investigator# 72314
-
Nizhny-Novgorod, Russian Federation, 603126
- Site Reference ID/Investigator# 71953
-
St. Petersburg, Russian Federation, 196247
- Site Reference ID/Investigator# 72315
-
St. Petersburg, Russian Federation
- Site Reference ID/Investigator# 72342
-
-
-
-
-
Badalona - Barcelona, Spain, 08916
- Site Reference ID/Investigator# 72368
-
Majadahonda (Madrid), Spain, 28222
- Site Reference ID/Investigator# 72366
-
-
-
-
Georgia
-
Savannah, Georgia, United States, 31405
- Site Reference ID/Investigator# 71894
-
-
Massachusetts
-
Worcester, Massachusetts, United States, 01655
- Site Reference ID/Investigator# 71897
-
-
New York
-
Manhasset, New York, United States, 11030
- Site Reference ID/Investigator# 71913
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599-7032
- Site Reference ID/Investigator# 71895
-
-
Ohio
-
Cleveland, Ohio, United States, 44106-5066
- Site Reference ID/Investigator# 71896
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria
Eligible subjects will be considered for inclusion in this study if they meet all of the following criteria:
- Males and females, 18 years of age or older.
- Diagnosis of ulcerative colitis (UC), as verified by endoscopy performed within 60 months prior to consent.
- Severe active disease, as defined by modified Truelove Witts severity index (MTWSI) >= 11 at consent, with a confirmatory MTWSI >= 10 on or after the fifth consecutive day of intravenous (IV) steroids and within 1 day prior to randomization.
- Mayo score >= 10 and Mayo mucosal subscore >= 2 after a minimum of 3 consecutive days (ie, on or after the fourth consecutive day) of IV steroids.
- Adequate contraception from the day of consent through 3 months after the last dose of study drug.
- Negative serum pregnancy test at screening.
- Negative Clostridium difficile test within 10 days prior to randomization.
- Signed and dated informed consent and Health Insurance Portability and Accountability Act (HIPAA) if applicable.
Exclusion Criteria
Subjects will be ineligible for this study if they meet any one of the following criteria:
- UC requiring immediate intervention.
- History of total proctocolectomy, or subtotal colectomy with ileorectal anastomosis
- Presence of ileostomy.
- White blood cell count less than 2.5 x 10^3/mcL; platelet count less than 150 x 10^3/mcL; or hemoglobin level less than 8 g/dL.
- Active medically significant infections, particularly those of viral etiology, eg, known cytomegalovirus (CMV) colitis. This includes any incidence of medically significant opportunistic infections within the past 12 months.
- Live vaccination within 6 weeks prior to randomization.
- Significant organ dysfunction, including cardiac, renal, liver, central nervous system (CNS), pulmonary, vascular, gastrointestinal, endocrine, or laboratory abnormality.
- History or treatment of lymphoproliferative disorder (LPD) or malignancy within the past 5 years (excluding nonmelanoma skin cancer or carcinoma in situ of the cervix).
- Seropositivity for infection with human immunodeficiency virus (HIV-1), hepatitis B virus (HBV) surface antigen, or hepatitis C virus (HCV).
- Pregnancy or nursing.
- Treatment with a first dose of infliximab or another anti-TNF-a drug within 4 weeks of randomization, or treatment with a subsequent dose of an anti-TNF-a drug within 2 weeks of randomization.
- Treatment with cyclosporine or tacrolimus (FK506) within 2 weeks prior to randomization.
- Treatment with any other investigational drugs or therapies within 60 days prior to randomization, except those mentioned in the two exclusion criteria above.
- Unwilling or unable to discontinue all UC drugs, except glucocorticoids and oral 5-ASA, immediately prior to randomization.
- Nontherapeutic levels of chronic antiseizure medications in subjects with a prior history of seizures.
- Any condition that, in the investigator's opinion, makes the subject unsuitable for study participation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Arm 1
Visilizumab low dose level
|
Visilizumab administered intravenously once per day for two days
Other Names:
|
|
Experimental: Arm 2
Visilizumab middle dose level
|
Visilizumab administered intravenously once per day for two days
Other Names:
|
|
Experimental: Arm 3
Visilizumab high dose level
|
Visilizumab administered intravenously once per day for two days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of subjects in each of the three visilizumab dose groups who respond to treatment in the dose-exploration portion of this study (Stage 1).
Time Frame: Day 45
|
Day 45
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Comparison of subjects in the three visilizumab dose groups
Time Frame: During the course of the study
|
During the course of the study
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Mihail Obrocea, MD, Abbott
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2006
Primary Completion (Actual)
November 1, 2007
Study Completion (Actual)
November 1, 2007
Study Registration Dates
First Submitted
March 24, 2006
First Submitted That Met QC Criteria
March 24, 2006
First Posted (Estimate)
March 28, 2006
Study Record Updates
Last Update Posted (Estimate)
April 27, 2012
Last Update Submitted That Met QC Criteria
April 26, 2012
Last Verified
April 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 291-418
- 2005-003482-17 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.